Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Lyndsay N Harris"'
Autor:
Robert Lindner, Catherine Sullivan, Onyinye Offor, Kimberly Lezon-Geyda, Kyle Halligan, Neal Fischbach, Mansi Shah, Veerle Bossuyt, Vincent Schulz, David P Tuck, Lyndsay N Harris
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e71915 (2013)
Triple negative breast cancer (TNBC) is characterized by high proliferation, poor differentiation and a poor prognosis due to high rates of recurrence. Despite lower overall incidence African American (AA) patients suffer from higher breast cancer mo
Externí odkaz:
https://doaj.org/article/4a94381861c3475db29ad350e4c60dd9
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Publikováno v:
Clinical Cancer Research. 29:1477-1483
Purpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combin
Autor:
Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
JCO precision oncology. 6
PURPOSE National Cancer Institute–Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family
Autor:
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Publikováno v:
Clinical Cancer Research. 29:1412-1422
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Autor:
Senthil, Damodaran, Fengmin, Zhao, Dustin A, Deming, Edith P, Mitchell, John J, Wright, Robert J, Gray, Victoria, Wang, Lisa M, McShane, Larry V, Rubinstein, David R, Patton, P Mickey, Williams, Stanley R, Hamilton, Jennifer M, Suga, Barbara A, Conley, Carlos L, Arteaga, Lyndsay N, Harris, Peter J, O'Dwyer, Alice P, Chen, Keith T, Flaherty
Publikováno v:
J Clin Oncol
Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated copanlisib,
Autor:
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John J. Wright, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jennifer M. Suga, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
Journal of Clinical Oncology. 40:1552-1561
PURPOSE Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated cop
Autor:
Michelle L. McGowan, Roselle S. Ponsaran, Paula Silverman, Lyndsay N. Harris, Patricia A. Marshall
Publikováno v:
BMC Medical Genomics, Vol 9, Iss 1, Pp 1-10 (2016)
Abstract Background Research suggests that multidisciplinary genomic tumor boards (MGTB) can inform cancer patient care, though little is known about factors influencing how MGTBs interpret genomic test results, make recommendations, and perceive the
Externí odkaz:
https://doaj.org/article/b49661ce9c1a412da7a10b5003ef4201
Autor:
Jeffrey A. Moscow, Lyndsay N. Harris, James H. Doroshow, Jordan Berlin, Timothy A. Yap, Petros Grivas, Keith T. Flaherty, Bhanumati Ramineni, Douglas S. Hawkins, Robert J. Gray, Stanley R. Hamilton, David Patton, James V. Tricoli, Gary H. Lyman, Julia Glade-Bender, Suzanne George, Roisin E. O'Cearbhaill, Boris Freidlin, Lisa M. McShane, Geoffrey I. Shapiro, Peter J. O'Dwyer, James M. Ford, Funda Meric-Bernstam
supplementary table TS1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11429ff581ea4e4e6669e078777ce535
https://doi.org/10.1158/1078-0432.22633057.v1
https://doi.org/10.1158/1078-0432.22633057.v1
Autor:
Jeffrey A. Moscow, Lyndsay N. Harris, James H. Doroshow, Jordan Berlin, Timothy A. Yap, Petros Grivas, Keith T. Flaherty, Bhanumati Ramineni, Douglas S. Hawkins, Robert J. Gray, Stanley R. Hamilton, David Patton, James V. Tricoli, Gary H. Lyman, Julia Glade-Bender, Suzanne George, Roisin E. O'Cearbhaill, Boris Freidlin, Lisa M. McShane, Geoffrey I. Shapiro, Peter J. O'Dwyer, James M. Ford, Funda Meric-Bernstam
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95ce7ea2922f53625334065386b4e22
https://doi.org/10.1158/1078-0432.c.6533210
https://doi.org/10.1158/1078-0432.c.6533210